Skip to main content Skip to navigation
Purified Mouse Anti-Human CD56
Product Details
Down Arrow Up Arrow


BD™
N-CAM; NCAM1; NCAM-1; Neural cell adhesion molecule 1; NKH1; MSK39
Human
Mouse BALB/c X C57BL/6 IgG1, κ
KG1a Cell Line
Flow cytometry
50 μg/mL
20 μL
V NK19
4684,916
Phosphate buffered saline with gelatin and 0.1% sodium azide.
RUO


Preparation And Storage

The monoclonal antibody is supplied as 100 µg purified immunoglobulin in 2.0 mL (50 µg/mL) of phosphate-buffered saline. The PE conjugate is supplied as 100 µg in 2.0 mL (50 µg/mL). Buffered saline contains gelatin and 0.1% sodium azide. The vials should be stored at 2° to 8°C. Conjugated forms should not be frozen and should be protected from prolonged exposure to light. Each reagent in stable for the period shown on the bottle labeled when stored as directed.

347740 Rev. 1
Antibody Details
Down Arrow Up Arrow
MY31

CD56, clone MY31, is derived from the hybridization of mouse Sp2/0 myeloma cells with spleen cells from (B6 x BALB/c) F1 mice immunized with the KG1a cell line.

CD56 recognizes an antigen present on natural killer (NK) lymphocytes that is the 140-kdalton (kDa) isoform of the neural cell adhesion molecule (NCAM). The 140-kDa core protein is extensively glycosylated to give a mature antigen.

347740 Rev. 1
Format Details
Down Arrow Up Arrow
Purified
Tissue culture supernatant is purified by either protein A/G or affinity purification methods. Both methods yield antibody in solution that is free of most other soluble proteins, lipids, etc. This format provides pure antibody that is suitable for a number of downstream applications including: secondary labeling for flow cytometry or microscopy, ELISA, Western blot, etc.
Purified
347740 Rev.1
Citations & References
Down Arrow Up Arrow

Development References (7)

  1. Edelman G. Cell adhesion molecules. Science. 1983; 219:450-457. (Biology).
  2. Hercend T, Griffin JD, Bensussan A, et al. Generation of monoclonal antibodies to a human natural killer clone. Characterization of two natural killer-associated antigens, NKH1A and NKH2, expressed on subsets of large granular lymphocytes.. J Clin Invest. 1985; 75(3):932-43. (Biology). View Reference
  3. Lanier LL, Chang C, Azuma M, Ruitenberg JJ, Hemperly JJ, Phillips JH. Molecular and functional analysis of human natural killer cell-associated neural cell adhesion molecule (N-CAM/CD56). J Immunol. 1991; 146(12):4421-4426. (Biology). View Reference
  4. Lanier LL, Le AM, Civin CI, Loken MR, Phillips JH. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol. 1986; 136(12):4480-4486. (Biology). View Reference
  5. Lanier LL, Testi R, Bindl J, Phillips JH. Identity of Leu-19 (CD56) leukocyte differentiation antigen and neural cell adhesion molecule. J Exp Med. 1989; 169(6):2233-2238. (Biology). View Reference
  6. Phillips JH, Lanier LL. Dissection of the lymphokine-activated killer phenomenon: relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J Exp Med. 1986; 164(3):814-825. (Biology). View Reference
  7. Schubert J, Lanier LL, Schmidt RE. Knapp W, Dörken B, Gilks WR, et al, ed. Leucocyte Typing IV: White Cell Differentiation Antigens. New York, NY: Oxford University Press; 1989:699-702.
View All (7) View Less
347740 Rev. 1

Please refer to Support Documents for Quality Certificates


Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Refer to manufacturer's instructions for use and related User Manuals and Technical Data Sheets before using this product as described.

Comparisons, where applicable, are made against older BD technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.